Skip to content

BIOMARIN PHARMACEUTICAL INC

BMRN

CIK 0001048477

← back to feed
Revenue (TTM)
$3.11B
+12.9% YoY Q1 Apr 2026
Net Income (TTM)
$501M
−18.3% YoY Q1 Apr 2026
EPS Diluted (TTM)
$2.56
−18.6% YoY Q1 Apr 2026
Gross Margin
79.5%
Q1 Apr 2026
Operating Margin
18.8%
Q1 Apr 2026
Net Margin
16.1%
Q1 Apr 2026
Free Cash Flow (TTM)
$279.83M
Q1 Apr 2026
Cash
$2.22B
Q1 Apr 2026
Total Debt
$1.43B
Q1 Apr 2026
Shares Outstanding
193.28M sh
Q1 Apr 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings